ROBIMYCIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROBIMYCIN (ROBIMYCIN).
Aminoglycoside antibiotic; binds to 30S ribosomal subunit inhibiting protein synthesis and causing mRNA misreading.
| Metabolism | Minimally metabolized; primarily eliminated unchanged by glomerular filtration. |
| Excretion | Renal (urine) 75-85% as unchanged drug; biliary/fecal 10-15%; minor metabolism. |
| Half-life | Terminal elimination half-life 1.5-2.5 hours (prolonged to 3-5 hours in renal impairment; no dose adjustment for mild-moderate impairment but caution in severe). |
| Protein binding | 30-40% bound primarily to albumin. |
| Volume of Distribution | 0.5-0.7 L/kg (moderate distribution; penetrates well into most tissues including lung, kidney, and bone). |
| Bioavailability | Intravenous: 100%; intramuscular: 90-95%; oral: 30-40% (due to first-pass metabolism; take on empty stomach). |
| Onset of Action | Intravenous: immediate; intramuscular: 30-60 minutes; oral: 1-2 hours. |
| Duration of Action | Intravenous/intramuscular: 6-8 hours; oral: 6-8 hours (dosing every 6-8 hours for infections). |
2.5-5 mg/kg IV every 6 hours; not to exceed 4 g/day.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | GFR >50: no adjustment; GFR 10-50: 2.5 mg/kg every 12 hours; GFR <10: 2.5 mg/kg every 24 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%. |
| Pediatric use | Neonates: 5 mg/kg IV every 12 hours; Infants and children: 5-7.5 mg/kg IV every 6 hours; max 4 g/day. |
| Geriatric use | Initiate at lower end of dosing range (2.5 mg/kg every 8 hours) due to age-related renal decline; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROBIMYCIN (ROBIMYCIN).
| Breastfeeding | Excreted into breast milk; M/P ratio not established. Potential for infant toxicity including hearing loss and renal impairment. Discontinue breastfeeding or avoid drug. |
| Teratogenic Risk | Robimycin is contraindicated in pregnancy. First trimester: Associated with major congenital malformations including cardiovascular and neural tube defects. Second and third trimesters: Risk of fetal ototoxicity and nephrotoxicity. Avoid use throughout pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
Boxed warnings: Increased risk of nephrotoxicity and ototoxicity (including irreversible bilateral vestibular and cochlear damage). Can cause fetal harm when administered to pregnant women. Patients should be carefully monitored for nephrotoxicity, ototoxicity, and neuromuscular blockade. Risk is higher with prolonged use, high doses, or pre-existing renal impairment.
| Serious Effects |
Hypersensitivity to aminoglycosides; myasthenia gravis; concurrent use with other nephrotoxic or ototoxic drugs; pregnancy (risk of fetal harm); pre-existing severe renal impairment (relative).
| Precautions | Nephrotoxicity: monitor renal function; ototoxicity: audiometric tests recommended; neuromuscular blockade: caution in myasthenia gravis or concurrent use of anesthetics/neuromuscular blocking agents; superinfection; avoid rapid intravenous administration; monitor serum levels to avoid toxicity. |
Loading safety data…
| Maternal: Renal function, hepatic function, audiometry, serum drug levels. Fetal: Ultrasound for malformations if exposed; neonatal audiometric screening and renal function tests after birth. |
| Fertility Effects | May cause reversible infertility in males due to spermatogenic suppression. No adequate data on female fertility; potential for ovarian toxicity. |